Common blood pressure drug could make cancer therapy far more powerful

Scientists have discovered that the widely used blood pressure medication telmisartan can greatly enhance the effectiveness of the cancer drug olaparib, which could benefit a broader range of cancer patients, not just those with BRCA mutations. This promising combination is now being evaluated in human clinical trials following impressive results in lab studies, where it showed significant immune-boosting and anticancer properties. The potential to improve cancer therapy through this combination could revolutionize treatment strategies and offer hope to many more patients.